Hadassah

BrainStorm Stem Cell Therapy for ALS is Fast-Tracked to New Phase

Thursday, Jan 24 2013

The ALS PhaseI/II safety trial of Brainstorm Cell Therapeutics' NurOwn stem cell therapy has been fast tracked to a Phase IIa dose-escalating trial by Israel's Ministry of Health and will be launched "immediately" at the Hadassah Medical Center, reports this leading developer of adult stem cell technologies for neurodegenerative diseases.

Prof. Dimitrios Karussis, Principal Investigator of BrainStorm's Phase I/II trial and head of the Multiple Sclerosis Center at Hadassah, commented: "Based on the positive results we have seen for the first 12 patients, we are eager to begin the next stage of clinical testing, and are delighted that the Ministry of Health has given us the green light to proceed to Phase IIa."

"Acceleration to Phase IIa will save us critical time, enabling us to proceed much more quickly with achieving our goal of developing an effective treatment for ALS," said Dr. Adrian Harel, BrainStorm's Chief Executive Officer.

In the Phase IIa trial, the second group of 12 patients from the initial cohort of 24 will receive combined intramuscular and intrathecal administration of NurOwn cells in three cohorts, with increasing doses. The study participants, who have already been recruited, will be followed for three to six months after transplantation.

BrainStorm plans to expand its clinical development to the United States in 2013, pending approval by the Food and Drug Administration. The company has entered into a Memorandum of Understanding with the University of Massachusetts Medical School and Massachusetts General Hospital to begin ALS human clinical trials at these medical facilities.

BrainStorm's NurOwn is a first-of-its-kind adult stem cell therapy for the treatment of neurodegenerative diseases derived from autologous bone marrow cells.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Thursday, May 16 2019

First of Its Kind in Israel: Cardiac Catheterization at Hadassah on Under Two-Pound Baby

A cardiac catheterization, the first of its kind in Israel, was successfully performed this week at Hadassah Hospital Ein Kerem on a fragile premature infant, weighing under two pounds.

READ MORE ›
alt_text

Wednesday, May 15 2019

How Much Do You Know About Your Liver and Hadassah’s Life-Saving Liver Treatments?

Three pounds of reddish-brown tissue tucked under the diaphragm, your liver churns out over 1,000 different types of enzymes to help you digest food, store energy, and wash out toxins

READ MORE ›
alt_text

Monday, May 13 2019

Grappling with Life Post-Trauma: Hadassah Therapist Offers Advice

As we return to normal life in the aftermath of terror attacks, whether in synagogues, churches, or other settings in our local communities, how do we cope?

READ MORE ›
alt_text

Thursday, May 9 2019

When Gender Is Ambiguous

Under the cover of darkness, an Arab family left Gaza for Hadassah Hospital Ein Kerem. Little Noor would return as little Ahmed.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More